Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Cepheid; BD; Transgenomic; Synthetic Genomics; Genetic Technologies; BioTime; Kiyatec; ABL

NEW YORK (GenomeWeb News) – Cepheid this week received CE marking for its Xpert CT/NG and Xpert CT tests, and the firm said it would begin shipping the tests in Europe immediately. The tests are for rapid detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhea and run on Cepheid's GeneXpert System.


The Board of Directors of Becton Dickinson has declared a quarterly dividend of $.45 per share. The dividend is payable on June 29 to shareholders of record on June 8.


Transgenomic has received CE IVD Mark registration for diagnostic use of its Wave MCE System and Surveyor Scan KRAS Kit, the firm said this week. The kit is being distributed in Europe by Transgenomic partner A. Menarini Diagnostics.


Synthetic Genomics this week said that it has purchased an 81 acre site, located in the Imperial Valley near the Salton Sea in Southern California, for scale up and testing of newly identified and engineered algal strains. The company will use the site to test algal strains isolated by SGI or developed through its synthetic genomic technologies, and to develop integrated processes for low-cost manufacturing of various algal products including food, flavorings, and nutritional products, said SGI.


Australian firm Genetic Technologies said this week that it has signed up four US preferred provider organizations to cover its BrevaGen breast cancer risk stratification test. The PPOs include Prime Health Services; National Preferred Provider Network/PlanCare America/Ohio Preferred Provider Network (NPPN/OPPN); Galaxy Health Network; and Fortified Provider Network.


BioTime said this week that it has completed the merger of Xennex with its LifeMap Sciences business. Xennex holds the exclusive rights to market the GeneCards and PanDaTox databases, developed at the Weizmann Institute. GeneCards is a searchable, integrated database of human genes that provides genomic, transcriptomic, genetic, proteomic, functional, and disease-related information on all known and predicted human genes.

BioTime announced separately that LifeMap Sciences has licensed from Weizmann a new database called MalaCards, which contains computerized cards classifying information related to a wide array of human diseases.


Kiyatec, a Greenville, SC-based developer of a 3D cell-based assay platform, has closed a Series A funding round. The firm declined disclose the amount raised in the round but said in a statement that the funds would be used to advance two of its 3D cell-based assays for more predictive evaluation of cancer efficacy and certain kinds of liver toxicity for drug and biologic candidates.


Advanced Biological Laboratories today said that its DeepChek and ViroScore Suite clinical genotyping solutions now have the CE-IVD Mark.

"The CE-IVD approval is in compliance with the latest European directives for medical devices, and positions DeepChek and ViroScore Suite as the first IT solutions choices to analyze comprehensive and complex data, thereby pioneering optimized personalized for the treatment of HIV," ABL CEO Chalom Sayada said in a statement.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.